Across TCGA pan-cancer cohorts, FGF7P7 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of FGF7P7’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where FGF7P7 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FGF7P7 is over-expressed in tumor.
LUAD are the cancer types where FGF7P7 tumor–normal differential expression is most reproducible.